ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,701 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentBaselSOTIO Biotech AG
SOTIO Biotech AG Logo
Verified· 2 sourcesTrust Score
Summary

About the company

The core activity of SOTIO is the development and research of oncological therapies, particularly in the field of biologics, such as antibody-drug conjugates (ADCs), immunocytokines and cell therapies. The company focuses on the development of drugs for the treatment of cancer and has built a pipeline of oncological programs driven by strategic licensing, M&A and internal discovery efforts.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

SOTIO Biotech AG

✓ Offered6
Targeted cancer therapies
Targeted cancer therapies with first-in-class and best-in-class potential, developed as mono- and bispecific antibody-drug conjugates and a PD-1 cis-targeted IL-15 immunocytokine.
Immunocytokine platform
Immunocytokine platform for preferential activation of immune cells in the tumor microenvironment through targeted delivery of a cytokine agonist.
IL-15 Superagonist candidates
IL-15 Superagonist candidates for oncology, including Nanrilkefusp alfa and SOT201, developed to expand cytotoxic T cells and NK cells.
Antibody-drug conjugates (ADCs)
Antibody-drug conjugate programs and technology for solid tumors, including proprietary and partnered ADC development platforms and multiple oncology candidates.
ADC technology
ADC technology combining proprietary antibodies with conjugation and linker-payload platforms from collaboration partners to research, develop, manufacture and commercialize ADC products.
Clinical development
Clinical development of oncology agents, including Phase 1 studies to assess safety, tolerability and preliminary efficacy.
Trust & reputation

ranQ Trust Score of SOTIO Biotech AG: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 54% · As of October 2026

Without public customer reviews the score stays capped.

SOTIO Biotech AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
SOTIO Biotech AG scores 85.1 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.75.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.96.07%
SOTIO Biotech AG scores 83.3 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).83.322%
SOTIO Biotech AG scores 100.0 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.100.04%
  • Media authority: No data point — the criterion is taken out of the weighting and does not lower the score.—4%
Qualifications+0.00

SOTIO Biotech AG reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 54%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Knowledge

No knowledge articles yet

Once SOTIO Biotech AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

SOTIO Biotech AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank SOTIO Biotech AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of SOTIO Biotech AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Lichtstrasse 35
4056 Basel

At a glance

Legal form
Corporation
UID
CHE-354.429.802
Founded
2019 · 7 years
Last commercial register change
July 17, 2026
Employees
101 to 500
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    CT
    ClearideBio Therapeutics AG
    Basel
    FT
    FoRx Therapeutics AG
    Basel
    NA
    NBE-Therapeutics AG
    Basel
    RS
    Regeneron Switzerland GmbH
    Basel
    WB
    Windward Bio 27 AG
    Basel
    FT
    Ferrosa Therapeutics AG
    Basel
    FA
    FimmCyte AG
    Basel
    PS
    PreClinical Safety (PCS) Consultants Ltd
    Basel